Skip to Content

Viokace Approval History

FDA Approved: Yes (First approved March 1, 2012)
Brand name: Viokace
Generic name: pancrelipase
Dosage form: Tablets
Company: Allergan plc
Treatment for: Pancreatic Exocrine Dysfunction

Viokace (pancrelipase) is a combination of porcine-derived lipases, proteases, and amylases. Viokace, in combination with a proton pump inhibitor, is indicated in adults for the treatment of exocrine pancreatic insufficiency due to chronic pancreatitis or pancreatectomy.

Development History and FDA Approval Process for Viokace

DateArticle
Mar  1, 2012Approval Aptalis Pharma Announces FDA Approval of Viokace (Pancrelipase) Tablets

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide